Avacta Therapeutics Collaborates with Tempus AI to Commence AI-Driven Drug Development in Oncology
Shots:
- The partnership gives Avacta access to Tempus’ multimodal datasets, containing primary tumor samples & related clinical data of 200,000 cancer patients, to study deep biology of tumor microenvironment & FAP activity for its pre|CISION tech
- The insights will enhance the platform reach by finding eligible patients for clinical studies. Tempus will help in data analysis through its analytical support & computational biology experts
- Additionally, Avacta has expanded its tech with two new preclinical programs, AVA6103 which is a PDC using exatecan (topoisomerase I inhibitor) to target tumors while minimizing harm to healthy tissues & AVA7100 which is an Affimer drug conjugate targeting cancers with varying FAP expression levels
Ref: Avacta & Tempus | Image: Avacta & Tempus
Related News:- Avacta Initiates P-I Clinical Trial of AVA6000 in Soft Tissue Sarcoma at Two US Clinical Investigator Sites
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
